AT354377T - An antitumor agent containing a cytostatic agent and a contrast- - Google Patents

An antitumor agent containing a cytostatic agent and a contrast-

Info

Publication number
AT354377T
AT354377T AT95905016T AT95905016T AT354377T AT 354377 T AT354377 T AT 354377T AT 95905016 T AT95905016 T AT 95905016T AT 95905016 T AT95905016 T AT 95905016T AT 354377 T AT354377 T AT 354377T
Authority
AT
Austria
Prior art keywords
contrast
agent
cytostatic
antitumor
containing
Prior art date
Application number
AT95905016T
Other languages
German (de)
Inventor
Regina Reszka
Uwe Pohlen
Detlef Stiller
Gerd Berger
Matthias Lippmann
Original Assignee
Max Delbrueck Centrum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE4341478A priority Critical patent/DE4341478C2/en
Application filed by Max Delbrueck Centrum filed Critical Max Delbrueck Centrum
Priority to PCT/DE1994/001524 priority patent/WO1996018421A1/en
Publication of AT354377T publication Critical patent/AT354377T/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/04X-ray contrast preparations
    • A61K49/0433X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0476Particles, beads, capsules, spheres
AT95905016T 1993-12-02 1994-12-16 An antitumor agent containing a cytostatic agent and a contrast- AT354377T (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE4341478A DE4341478C2 (en) 1993-12-02 1993-12-02 Means for anti-tumor therapy
PCT/DE1994/001524 WO1996018421A1 (en) 1993-12-02 1994-12-16 Anticancer drug with a cytostatic and a contrasting agent

Publications (1)

Publication Number Publication Date
AT354377T true AT354377T (en) 2007-03-15

Family

ID=6504258

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95905016T AT354377T (en) 1993-12-02 1994-12-16 An antitumor agent containing a cytostatic agent and a contrast-

Country Status (2)

Country Link
US (1) US6479033B1 (en)
AT (1) AT354377T (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
DE10115740A1 (en) 2001-03-26 2002-10-02 Ulrich Speck Preparation for the prophylaxis of restenosis
DE10244847A1 (en) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck A medical device for drug delivery
AU2003301077B2 (en) * 2002-12-18 2009-12-24 Hough Ear Institute Otologic nanotechnology
US7462703B2 (en) * 2003-01-31 2008-12-09 Max-Delbruck-Centrum Fur Molekulare Medizin Agent for gene transfer
WO2005063304A2 (en) * 2003-12-24 2005-07-14 Board Of Regents, The University Of Texas_System Poly (l-glutamic acid) paramagnetic material complex and use as a biodegradable mri contrast agent
PL2233150T3 (en) * 2003-12-30 2017-06-30 Bader Erythropoietin for use in the treatment of wounds or the transplantation of cells
US20050255045A1 (en) * 2004-05-13 2005-11-17 Woltering Eugene A Surgical marking composition and method
EP2014728A1 (en) 2005-01-13 2009-01-14 Cinvention Ag Composite material coatings
AU2006232318A1 (en) * 2005-04-01 2006-10-12 The Board Of Regents Of The University Of Texas System Poly(peptide) as a chelator: methods of manufacture and uses
BRPI0617450A2 (en) * 2005-10-18 2011-07-26 Cinv Ag thermosetting particles and methods for their production

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5213788A (en) * 1988-09-29 1993-05-25 Ranney David F Physically and chemically stabilized polyatomic clusters for magnetic resonance image and spectral enhancement
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5620703A (en) 1991-10-11 1997-04-15 Max-Delbruck-Centrum Fur Molekulare Medizin Stimulating hematopoietic activity with carboplatin or lobaplatin
DE4341478C2 (en) * 1993-12-02 1998-10-08 Max Delbrueck Centrum Means for anti-tumor therapy
DE19724796A1 (en) * 1997-06-06 1998-12-10 Max Delbrueck Centrum Means for anti-tumor therapy

Also Published As

Publication number Publication date
US6479033B1 (en) 2002-11-12

Similar Documents

Publication Publication Date Title
DE10299013I2 (en) Aza-Zyklohexapeptide
DE69406956D1 (en) absorbent articles
DE69411990D1 (en) Microstructure Vibratordrehmessaufnehmer
DE69432732D1 (en) Modular radio transmission arrangement
DE69412468D1 (en) ostomy
DK0677056T3 (en) Oligonucleotide alkylphosphonates and -alkylphosphonothioater
DK0679319T3 (en) Telekommunikationsswich with progammer just communication features
AT282366T (en) Wirbeldistraktor
AT281812T (en) Hydrogelwundverband
AT182420T (en) Sprachaktivitaetsdetektor
AT188809T (en) Festoxidbrennstoffzellenstrukturen
AT237390T (en) Fibrinogenextraktion
DE59400921D1 (en) Saugbagger
AT200872T (en) Abrasivstrahlströmungsschneider
AT178362T (en) Sanitaereinrichtungen
AT235555T (en) Aspertokinasegenvarianten
AT156895T (en) microvalve
DE69432396D1 (en) An acceleration
DK0703761T3 (en) stent
DK0637265T3 (en) catalytic carbon
DE69429722T2 (en) Quick oven
DE69429464D1 (en) Bildverarbeitungsverfahren- and gets
DE69430635D1 (en) Loteprednol etabonate-suspension
DE59409409D1 (en) inhaler
DK0728132T3 (en) Anti-thrombotic amidinophenylalanin- and amidinopyridylalaninderivater

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee